An objective assessment of botulinum toxin type A injection in the treatment of post-facial palsy synkinesis and hyperkinesis using the synkinesis assessment questionnaire
| Autor: | Vanessa Venables, Ruben Kannan, Margaret Aslet, Charles Nduka, Catriona Neville |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
medicine.medical_specialty Synkinesis Facial Paralysis Facial Muscles complex mixtures Injections Intramuscular Hyperkinesis Botulinum toxin a Objective assessment 03 medical and health sciences 0302 clinical medicine Paired samples Surveys and Questionnaires medicine Humans Botulinum Toxins Type A 030223 otorhinolaryngology Palsy business.industry medicine.disease Botulinum toxin Facial paralysis Surgery Treatment Outcome Neuromuscular Agents 030220 oncology & carcinogenesis Physical therapy Female business medicine.drug |
| Zdroj: | Journal of plastic, reconstructiveaesthetic surgery : JPRAS. 70(11) |
| ISSN: | 1878-0539 |
| Popis: | This study aimed to provide reliable and valid evidence that botulinum toxin type A (BTX-A) is a successful treatment for facial synkinesis in facial palsy by using the synkinesis assessment questionnaire (SAQ) tool. Fifty-one patients completed questionnaires pre- and post-BTX-A treatment over 103 cycles of treatment. Each patient was individually assessed and then treated according to their presenting symptoms with a dosage in each injection site of between 0.5 and 5 U of BTX-A. A two-tailed paired samples t-test was used to compare the scores for each question before and after treatment. A significant difference was found between all scores before and after treatment at the level of p 0.05. There was not only an improvement in the mean score in the post-treatment group but also a smaller spread of scores in the post-treatment group than in the pre-treatment group. The study showed that SAQ scores decreased significantly for every question on the SAQ after treatment. This indicates that BTX-A is an effective treatment for synkinesis, adding further weight to current evidence. The study also indicated that BTX-A continues to be effective even after three rounds of treatment, with a significant decrease in overall scores after each treatment cycle. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect